Logos Global Management’s Black Diamond Therapeutics BDTX Stock Holding History

Logos Global Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-123,465	Closed	-$3.96M	–	56
2020 Q4	$3.96M	Hold	123,465	–	–	0.34%	40
2020 Q3	$3.73M	Hold	123,465	–	–	0.48%	36
2020 Q2	$4.68M	Hold	123,465	–	–	0.94%	32
2020 Q1	$2.77M	Buy	+123,465	New	+$3.76M	1.05%	32

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Logos Global Management's BDTX Position: Q1 2021 in Review

Logos Global Management sold out of Black Diamond Therapeutics (BDTX) in Q1 2021, closing a stake of 123,465 shares — an estimated $3.96M sold.

Logos Global Management first reported a position in BDTX in Q1 2020 and held it in 4 quarters. The position peaked at $4.68M in Q2 2020. 113 funds tracked by Wall St. Rank hold BDTX as of Q1 2021.

Logos Global Management reported no remaining Black Diamond Therapeutics position as of Q1 2021 after selling out during the quarter.
Logos Global Management sold 123,465 Black Diamond Therapeutics shares in Q1 2021, an estimated $3.96M.
Logos Global Management first reported a position in Black Diamond Therapeutics in Q1 2020 and held it in 4 quarters.
Logos Global Management's Black Diamond Therapeutics position peaked at $4.68M in Q2 2020.
113 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2021.

Based on Logos Global Management's 13F filing for Q1 2021, filed 17 May 2021.